文献速递介入腹部外周血管USMRCT

基于超分辨超声成像与大鼠肝细胞癌模型评估经动脉化疗栓塞术

Assessment of Transarterial Chemoembolization Using Super-resolution Ultrasound Imaging and a Rat Model of Hepatocellular Carcinoma.
PubMed 文献 · Ultrasound Med Biol · 2023-03-01

本研究在大鼠原位肝细胞癌模型中,用纵向超分辨超声(SRUS)和MRI在0、7、14天评估多柔比星-碘油乳剂TACE的治疗反应。完全缓解者14天时微血管密度和肿瘤大小均低于部分缓解者和对照组;组织学肿瘤坏死比例对照组8.4%、部分缓解组51.1%、完全缓解组100%(P<0.005)。SRUS有望评估TACE等改变组织灌注干预后的微血管网络早期变化。

要点

  • SRUS可显示10至100微米级微血管结构,突破传统超声衍射极限。
  • 14天时完全缓解者微血管密度和肿瘤大小均低于部分缓解者和对照组。
  • 组织学肿瘤坏死比例对照组8.4%、部分缓解组51.1%、完全缓解组100%。

核心结论

  • SRUS成像有望用于评估TACE等改变组织灌注干预后肝细胞癌微血管网络的早期变化。

研究设计与样本

  • 大鼠原位肝细胞癌模型研究,纵向SRUS和MRI于0、7、14天评估多柔比星-碘油乳剂TACE治疗反应,14天处死动物行组织学分析确定TACE反应(对照、部分缓解或完全缓解)。

关键影像表现/征象

  • SRUS可增强10至100微米级较小微血管结构的可见细节。
  • 14天时完全缓解者的微血管密度水平和肿瘤大小测量值分别 considerably 低于和小于部分缓解者或对照组动物。

诊断标准与关键数值

  • 基线时各组间无差异(p > 0.15)。
  • 组织学肿瘤坏死比例:对照组8.4%、部分缓解组51.1%、完全缓解组100%(p < 0.005)。

临床应用与阅片要点

  • CEUS成像使用临床前超声系统(Vevo 3100,FUJIFILM VisualSonics公司)配MX201线阵换能器,注射微泡造影剂(Definity,Lantheus Medical Imaging)后换能器以100微米步进机械移动采集系列CEUS图像。
  • SRUS图像在每个空间位置形成并计算微血管密度指标,微CT用于确认TACE手术成功,小动物MRI系统(BioSpec 3T,Bruker公司)监测肿瘤大小。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Hepatocellular carcinoma (HCC) is a highly prevalent form of liver cancer diagnosed annually in 600,000 people worldwide. A common treatment is transarterial chemoembolization (TACE), which interrupts the blood supply of oxygen and nutrients to the tumor mass. The need for repeat TACE treatments may be assessed in the weeks after therapy with contrast-enhanced ultrasound (CEUS) imaging. Although the spatial resolution of traditional CEUS has been restricted by the diffraction limit of ultrasound (US), this physical barrier has been overcome by a recent innovation known as super-resolution US (SRUS) imaging. In short, SRUS enhances the visible details of smaller microvascular structures on the 10 to 100 µm scale, which unlocks a host of new clinical opportunities for US.

METHODS: In this study, a rat model of orthotopic HCC is introduced and TACE treatment response (to a doxorubicin-lipiodol emulsion) is assessed using longitudinal SRUS and magnetic resonance imaging (MRI) performed at 0, 7 and 14 d. Animals were euthanized at 14 d for histological analysis of excised tumor tissue and determination of TACE response, that is, control, partial response or complete response. CEUS imaging was performed using a pre-clinical US system (Vevo 3100, FUJIFILM VisualSonics Inc.) equipped with an MX201 linear array transducer. After administration of a microbubble contrast agent (Definity, Lantheus Medical Imaging), a series of CEUS images were collected at each tissue cross-section as the transducer was mechanically stepped at 100 μm increments. SRUS images were formed at each spatial position, and a microvascular density metric was calculated. Microscale computed tomography (microCT, OI/CT, MILabs) was used to confirm TACE procedure success, and tumor size was monitored using a small animal MRI system (BioSpec 3T, Bruker Corp.).

RESULTS: Although there were no differences at baseline (p > 0.15), both microvascular density levels and tumor size measures from the complete responder cases at 14 d were considerably lower and smaller, respectively, than those in the partial responder or control group animals. Histological analysis revealed tumor-to-necrosis levels of 8.4%, 51.1% and 100%, for the control, partial responder and complete responder groups, respectively (p < 0.005).

CONCLUSION: SRUS imaging is a promising modality for assessing early changes in microvascular networks in response to tissue perfusion-altering interventions such as TACE treatment of HCC.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Brown, Li, Margolis, et al. Assessment of Transarterial Chemoembolization Using Super-resolution Ultrasound Imaging and a Rat Model of Hepatocellular Carcinoma. Ultrasound Med Biol. 2023. PMID: 36868958. doi:10.1016/j.ultrasmedbio.2023.01.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。